Format

Send to

Choose Destination
See comment in PubMed Commons below
Asian J Androl. 2012 May;14(3):361-4. doi: 10.1038/aja.2011.151. Epub 2012 Apr 16.

Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Author information

1
Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan. kakehi@med.kagawa-u.ac.jp

Abstract

Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the patients who may or may not benefit from immediate treatment interventions at the time of the initial diagnosis. The selection of candidate patients who can postpone immediate treatment and undergo follow-ups with a specific surveillance program, or 'active surveillance,' is a practical way to minimize overtreatment. In this review, the benefits and risks of active surveillance are discussed. Future perspectives, including imaging and new biomarkers for improving the outcomes of active surveillance programs, are also discussed.

PMID:
22504873
PMCID:
PMC3720161
DOI:
10.1038/aja.2011.151
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Support Center